News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

RDW Group Receives Five Bell Ringer Awards

RDW Group

RDW Group accepted a total of five Bell Ringer awards during the PR Club ’s 54th annual ceremony, held last month at the Royal Sonesta Boston. The Bell Ringer Awards recognize public relations and communications campaigns demonstrating excellence in planning, strategy, execution, and outcomes. RDW received awards for five campaigns and initiatives conducted throughout 2021: Business-to-Consumer (B2C) Social Media Silver Bell: RDW Group with Rhode Island Medical Imaging for “Sharing the Unseen Through Social Media” Bronze Bell: RDW Group with Ageless Innovation for “Supporting Caregivers and Older Adults Through Social Media” Mega Influencer Bronze Bell: RDW Group with Ageless Innovation for “Social Media Influencers Help Raise Awareness of Joy for All Companion Pets” Healthcare Campaign Bronze Bell: RDW Group with the Rhode Island Department of Health for the “Rhode Island Department of Health Substance Exposed Newborns Campaign” One-Time Special Event Merit: RDW Group with Rhode Island Medical Imaging for “Rhode Island Medical Imaging and Providence College Basketball Pink Out Friartown” “RDW is proud to, once again, be recognized alongside our clients as Bell Ringer recipients,” said RDW Group’s managing partner, Phil Loscoe, Jr. “The collaborative work of our teams is not only award-winning, but more importantly is proven to be making a positive impact on our communities. There is no better reward.” The Bell Ringer event was hosted by Brianna Borghi, on-air reporter for NBC5, Burlington, VT. In addition to the Bell Ringer awards, the Pub Club announced winners of its Striker and Ringer professional awards and its John J. Molloy Crystal Bell for lifetime achievement award. “The excellence of our New England PR community shines through in this year’s Bell Ringer Award winners,” said Amanda Fountain, PR Club president and digital engagement lead at LEGO Education. “This year feels extra special as we returned to celebrating the incredible work and professionals in-person after two years of virtual events. The format of the Bell Ringer presentation may have adapted to the times, but the quality of the work and dedication of the individuals who do it is consistently impressive.” View all 54 th annual Bell Ringer Award recipients at prclub.org/blog/54th-bell-ringer-awards-concludes. Learn more about RDW Group at rdwgroup.com. RDW Group was founded in 1986, and is a full-service advertising, public relations and media services agency with offices in Providence and Boston. RDW also operates iFactory, an award-winning web strategy, design and development group in Boston. More info at rdwgroup.com. Contact Details RDW Group Giselle Mahoney +1 401-829-8321 gmahoney@rdwgroup.com Company Website https://rdwgroup.com

July 19, 2022 09:13 AM Eastern Daylight Time

Article thumbnail News Release

Asia’s only diagnostic-first sexual health wellness startup Kindly secures funding round

Kindly

Health tech startup Kindly has set out to support men and women across asia dealing with sexual lifestyle disorders and fertility issues with a diagnostic-first approach. As they seek to grow and expand, Kindly has today announced a $3.25M seed round from investors around the world including Y Combinator, DG Daiwa, Olive Tree, Soma, Goodwater, and Gaingels. Founded in 2020 (previously known as Janani.life), Kindly is a holistic sexual performance and a lifestyle brand focussed on the sexual & reproductive health space. They are addressing the gap in the market of lifestyle disorders, sexual performance, and hormonal wellness – a $8b market opportunity - with their support and product range. The YCombinator (W22 cohort) backed start-up, Kindly is Asia’s only diagnostics-first lifestyle brand offering a full-stack sexual wellness solution, including at-home diagnostics, convenient expert consultations, and doctor-backed supplements. Kindly is the only brand in India to offer at-home-semen tests that are not only focused on fertility issues but also on lifestyle disorders, which are extremely common among men and women today. Kindly is addressing a marketplace of 130 million users in India alone who will benefit from Kindly’s full stack approach by early diagnosis of lifestyle disorder, expert doctor consultations and research backed supplements to overcome and manage lifestyle disorders such as sexual dysfunctions, low vitality, PCOS and menstrual pain. Nilay Mehrotra, Founder & CEO of Kindly, commented: “We’ve attracted investors from around the world and this bodes well for our expansion into markets beyond India. The whole team is passionate about empowering people to explore their sexual wellness safely and confidently and this shows in our community engagement and growth numbers. We’re breaking new ground with an all-inclusive approach to lifestyle and sexual disorders, something which hasn’t been done before. The funding round wil elevate us from from a disruptor brand to a market leader in the lifestyle and sexual wellness market. With fresh product lines, a tech-enabled platform for easy access to our services, and our intention for global expansion, we are poised to enter the next phase of our growth.” Kindly’s offerings are categorised into KindlyHis and KindlyHers to address the needs of both genders. KindlyHis is predominantly leading the conversation about sexual performance and sperm health whereas KindlyHers focuses on women’s holistic wellness offering products and services for sexual, menstrual, and hormonal wellness. Both men and women face sexual wellness concerns but due to lack of awareness and social stigma associated with these problems they refrain from seeking help. Erectile dysfunction, premature ejaculation and loss of libido are one of the major concerns for men. According to research, Prevalence of female sexual dysfunction increased with age, from 22% in women aged <20 years to 75.7% in women aged 40-50 years. Most women suffer from painful sex, vaginusmus, vaginal dryness and loss of libido but in most cases it is ignored due lack of knowledge. Kindly will use the capital to accelerate its growth and expansion across India and international markets. “As a growth-stage investor focused on bio health led businesses, we are excited to partner with Kindly. The wellness market has changed dramatically over the last year, and we believe the demand for at home diagnostics will only continue to grow. Kindly's diagnostics first based model is well positioned for success, and we believe it has the potential to grow” added Takeshi Kanamori, Managing Director, DG Daiwa ventures. About Kindly Kindly is a holistic sexual performance and a lifestyle brand for all, offering discreet, non-judgmental, convenient, end-to-end full-stack solutions. Launched in May 2022 by Nilay Malhotra and Raj Garg, the Bengaluru-based start-up provides an end-to-end, research-backed solution for sperm health & sexual performance for men, PCOS, irregular periods & period pain for women, and low libido for women. Kindly has two verticals: Kindly His and Kindly Hers. Kindly His is predominantly leading the conversation about sexual performance and sperm health whereas Kindly Hers focuses on women’s holistic wellness offering products and services for sexual, menstrual, and hormonal wellness. For more information, please visit: https://www.kindlyhealth.com/ Contact Details Kindly Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.kindlyhealth.com/

July 14, 2022 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Elsevier Launches Global Collaboration to Understand the Impact of the Pandemic on Confidence in Scientific Research

Elsevier

Elsevier, a global leader in research publishing and information analytics, has today announced the launch of a global collaboration that will include new, independent research led by Economist Impact. The initiative aims to assess the drivers of confidence in research, examine how researchers have experienced the increased public attention on science during the pandemic, and the implications this has had on the academic research community. It is also looking at changes in the ways in which researchers communicate their findings. A main focus of the initiative will be a landmark global survey conducted by Economist Impact, experts in helping to identify critical and actionable insights, of 3,000 researchers across Europe, North America, Latin America, Middle East, Africa, and Asia. The insights will be published in a free report in Autumn 2022, and be used to create a set of actionable commitments and recommendations that will support researchers in their efforts to advance knowledge that benefits society. The initiative sees Elsevier partner with Sense about Science, which has pioneered wider engagement on the reliability of research internationally, to bring together world-renowned experts to advise and inform the collaboration via a Global Advisory Board tasked with shaping the primary research, and a Global Expert Panel that will drive the co-creation of actionable insights and recommendations to benefit the research community. Elsevier is also working in partnership with leading science and research organisations in six regions: Chinese Association for Science of Science and Science & Technology Policy (China) Körber Stiftung (Germany) Japanese Association for the Advancement of Science (Japan) Koninklijke Hollandsche Maatschappij der Wetenschappen - Royal Holland Society of Sciences and Humanities (Netherlands) Sense about Science (UK & global) Research!America (US) These organisations will bring unique perspectives from their respective countries, and co-host roundtables with Elsevier to explore the findings and discuss potential recommendations the collaboration will put forward. Anne Kitson, Senior Vice President and Managing Director of Cell Press and The Lancet, Elsevier said: “Ensuring quality research can accelerate progress for society is at the heart of what Elsevier does. Science is making extraordinary advances at an accelerated pace, but amid this change lie new challenges for researchers. We’re privileged to partner with and bring together some of the world’s leading experts to consider these challenges, and work towards recommendations that we hope will help researchers to navigate this fast-evolving scientific landscape.” Tracey Brown, Director, Sense about Science, said: “This work builds on our long-standing collaboration with Elsevier to support initiatives that improve understanding of research quality and accessible findings. If researchers have questions about the reliability of research on which to build, then these are also questions for the public and how we more broadly place confidence in findings. We are looking to this initiative to provide more of an evidence base on which initiatives can be developed and benchmarked.” Jonathan Birdwell, Regional Head of Policy Research & Insights for EMEA, Economist Impact said: “2020 was a landmark year for scientific research. The development of Covid-19 vaccines marked an extraordinary achievement for science and global scientific cooperation. The pandemic turned previously unknown researchers into household names, with politicians, business leaders and the general public more invested than ever before in the outcomes of the scientific process. But the pandemic also appears to have accelerated a number of longer-term trends affecting the research community, including the speed and volume of research published and the role of social media. What impact has the pandemic had on how researchers produce and communicate their research? How do researchers’ experiences differ by geography, gender identity and career stage? What types of tools and resources do researchers need to produce and communicate research effectively? Our research hopes to answer these questions and identify solutions that could help researchers navigate this changing landscape with confidence.” The collaboration comes as Elsevier’s Research Futures report reveals that the most cited ‘red flags’ for researchers to engage with and trust research was the source of data being unclear (60%), the journal being of low quality (57%) and the research not being peer reviewed (55%). The report, which surveyed over 1,000 researchers globally, also found that the most stated challenges to effective communication of research were pressure to publish to advance your career (63%), the sheer volume of articles being published (51%), and the growing emphasis on demonstrating novelty in research (47%). Researchers also reported an increase in their use of sharing sites, academic community platforms, and publisher websites. --- Notes to editors Global Advisory Board members include: Dr. Agnes Binagwaho, Vice-Chancellor, University of Global Health Equity, Rwanda Dr. Cary Funk, Director of science and society research, the Pew Research Center Dr. John Grove, Director of Quality Assurance for Norms & Standards, World Health Organisation Dr. Heide Hatheckmann, Senior Advisor for Transdisciplinarity and Global Knowledge Networks, Centre for the Advancement of Scholarship of the University of Pretoria and Interim Director for Future Africa. Dr. Richard Horton, Editor-in-chief, The Lancet Dr. Reiko Kuroda, Professor at Chubu University, Japan and Professor Emeritus at The University of Tokyo Dr. Nick Perkins, Board Member, International Science Council Dr. John Pham, Editor-in-chief, Cell Dr. Wim van Saarloos, Chair of the Energy Programme, European Academies Science Council (EASAC); Professor of theoretical physics, the Instituut-Lorentz, University of Leiden Dr. Michael Saliba, Professor and Head of the Institute of Photovoltaics, University of Stuttgart and Co-chair, Global Young Academy Dr. Karla Soares-Weiser, Editor-in-chief, Cochrane Dr. Jack Stilgoe, Professor of Science and Technology Policy, Dept of Science & Technology Studies, Faculty of Maths & Physical Sciences, University College London Dr. Sheila Jasanoff, Pforzheimer Professor of Science and Technology Studies, John F. Kennedy School of Government, Harvard University About Sense about Science Sense about Science is an independent non-profit that promotes the public interest in sound science and evidence. It produced the first public guide to peer review, ‘I Don’t Know What to Believe’ over a decade ago, and has since produced the first international guide to data science, co-created with user groups around the world. With its AllTrials campaign, with patients, doctors and researchers, it has achieved major changes in international regulation and compliance on the publication of clinical trial results. Sense about Science will chair the Global Expert Panel, to develop plans for improving scientific practices and helping researchers and the public to navigate research outputs. It will represent UK-based stakeholders as the local Regional Convening Partner, to draw people into a discussion of what actions and interventions researchers, scholarly publishers, universities, funders and others can make to improve confidence in research in the UK. About Economist Impact Economist Impact combines the rigour of a think-tank with the creativity of a media brand to engage a globally influential audience. We believe that evidence-based insights can open debate, broaden perspectives and catalyse progress across three core areas of expertise and leadership including sustainability, new globalisation and health. The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events and SignalNoise. Our track record spans 75 years across 205 countries. Along with creative storytelling, events expertise, design-thinking solutions and market-leading media products, we produce framework design, benchmarking, economic and social impact analysis, forecasting and scenario modelling, making Economist Impact's offering unique in the marketplace. Visit www.economistimpact.com for more information. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Andrew Davis andrew.davis@elsevier.com Andrea White a.white@elsevier.com Company Website https://www.elsevier.com/

July 13, 2022 04:00 AM Eastern Daylight Time

Article thumbnail News Release

Nearly Half a Million Young People Are Quitting E-cigarettes Through Text: First-of-its-kind program from truth® is helping young people quit vaping nicotine

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/qb2xLRu2VOQ E-cigarette use among young people remains at epidemic levels with nearly one in five high school students using e-cigarettes and approximately 40% of users doing so on a regular basis, according to recent data. What can be done to turn around this troubling trend? Text message programs are available to help young people on their quitting journey. This is Quitting from truth is a free and anonymous text messaging program designed to help young people quit vaping nicotine. The first-of-its-kind quit program incorporates messages from real young people like them who have attempted to, or successfully quit, e-cigarettes. Results from a clinical trial demonstrate the effectiveness of the program and found that This is Quitting from truth increased quit rates among young adults aged 18-24 by nearly 40% compared to a control group. How it works To enroll in This is Quitting, teens and young adults can text DITCHVAPE to 88709. The first messages they receive will ask for their age and product usage so that they are able to receive relevant messages. Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those who are not ready to quit receive at least four weeks of messages focused on building skills and confidence. Users with a quit date receive one week of messages prior to that date and at least eight weeks of messages after their quit date. Throughout the program, users can text COPE, STRESS, SLIP or MORE to receive instant support. Upon completion of the program, users receive periodic text messages from truth and may continue to use supportive keywords for as long as they like. For more information, visit TRUTHINITIATIVE.ORG Teens and young adults can join for free by texting DITCHVAPE to 88709. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

July 11, 2022 04:00 PM Eastern Daylight Time

Video
Article thumbnail News Release

‘Ready for Ron’ Releases Research Illustrating Growing Positive Sentiment for DeSantis

Ready for Ron

Today, Ready for Ron, a draft committee encouraging Florida Governor Ron DeSantis to run for President, released research it commissioned from Impact Social showing growing support for Governor DeSantis. The report shows positive sentiment for Governor Ron DeSantis grew 8 points from an earlier analysis released last week. Impact Social researchers analyzed the publicly available social media discussion in relation to Ron DeSantis and Donald Trump among swing voters from June 15 to June 29, 2022. Additional reports are expected every two weeks. Previous reports can be found here. “We carried out detailed language analysis of US social media discussions back to May 2016 to capture social media users into a database of 40,000 swing voters,” explained Phil Snape, Director at Impact Social. “With 40,000 participants, we are operating what is likely the world’s largest focus group – as big as a Football stadium.” The summary of Impact Social’s second report states: The last fortnight has been a productive period for Ron DeSantis which has seen his net sentiment jump 8 pts (-14 to -6) among floating voters. Within the positive conversation (+2pts 19 to 21), those hoping to persuade DeSantis to run for president will be delighted to see the leading topic within this discussion is how they prefer DeSantis to Trump (33%). It is worth emphasizing these opinions are posted without coercion or provocation. These floating voters are merely stating online how they favor the younger man as their next president. A small percentage (4%) are even outing themselves as Democrats before volunteering their support should DeSantis stand. Intriguingly, there is a feeling among his supporters that a sense of momentum is developing around his potential presidential candidacy. They speak excitedly about a poll in NH, an ‘endorsement’ by Elon Musk or simply muse that DeSantis’ ‘is where the smart money is’, that ‘Dems want Trump because they can’t beat DeSantis’ or that Fox will happily anoint him as leader of the GOP when the time arises. A downward trend in the number of negative posts against DeSantis (-5pts 33 to 27) will be welcomed by his camp. Yet their boss continues to take hits from across the political spectrum as some GOP voters see him as too right wing and pine for a leader dedicated to smaller government. That said, the majority of criticism stems from the left who see DeSantis as an overbearing authoritarian. They use DeSantis’ recent decision not to order Covid -19 vaccination for FL kids as a prime example of what he is capable of. This, together with perceived attacks on LGBT rights and support for gun laws increases anxiety among the left many of whom see him as a danger to America. All of which, given the ideological standpoint of the authors, might be music to DeSantis’ ears. “We are excited to see our efforts are paying off. Support for Ron DeSantis continues to grow. While we expect the attacks to increase, we are delighted his support base is increasing too,” explained Ready for Ron legal counsel and spokeswoman Lilian Rodríguez-Baz. “We are hoping to build one of the biggest grassroots movements ever, and with support growing like this, it will happen even more quickly than we anticipated.” Ready for Ron continues its TV and online advertising efforts to engage Americans to sign the petition at ReadyForRon.com to Draft Ron DeSantis to run in 2024. While ‘Ready for Ron’ is completely unaffiliated with the DeSantis campaign per federal regulations, it has taken the novel step of submitting a formal Advisory Opinion Request to the FEC seeking to share its growing supporter list with Governor DeSantis if the Draft succeeds and he announces his candidacy. Impact Social is a specialist social media, online monitoring, and analysis company. It uses big data software to track over 60 million online sites including Twitter, Facebook, all blogs, forums, and news websites. Whatever is said publicly, in the media or online it can follow live, 24/7 in 44 different languages. This is where reliance on algorithms ends. Once the data has been received its in-house experts read and analyze the content - often amounting to 1,000’s of individual posts. Impact Social’s unique methodology ensures unrivalled accuracy to show what has been said and its impact. Impact Social is the only company in the world providing this level of analysis. ### For more information or to schedule an interview with ‘Ready for Ron’ legal counsel, Lilian Rodríguez-Baz, or an Impact Social spokesperson, please contact Dan Rene at 202-329-8357 or dan@readyforron.com Contact Details Dan Rene +1 202-329-8357 dan@readyforron.com Company Website https://www.readyforron.com/

July 11, 2022 10:17 AM Eastern Daylight Time

Article thumbnail News Release

First version of the SleepX APP has been uploaded to the Google Play Store

Appyea

SleepX, a subsidiary of AppYea (OTC: APYP) a Company that is focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces that the first version of the SleepX APP has been uploaded to the Google Play Store. Without a wristband, the current version can be used for breath monitoring, snoring detection and intensity, as well as the amount of snoring per sleep session. The app also provides the user a breathing graph as well as a recording each sleep session. The app is available for free download for all versions of Android starting with version 7.0. "We decided to upload the first version for free, to increase people awareness of the importance of quality of proper breathing during sleep," said Bary Molchadsky, founder of SleepX and chairman of AppYea. “Poor sleep is associated with a compromised immune system, heart problems, reduced physical and mental performance, mood problems, obesity and many other health problems”, said Neil Kline, Founder & former CEO of the American Sleep Association, and a AppYea Board Member. “Unfortunately, most people with sleep disorder breathing problems, like sleep apnea, are undiagnosed and untreated. Our goal with this unique technology is to raise awareness and improve sleep quality so individuals can live healthier and more fulfilling lives.” Free download the SleepX APP for Android AppYea continues in-depth tests and calibration of DreamIT, its wearable data-driven wristband to treat snoring. The wearable contains a vibration motor and sensors that measure real-time physiological indications such as movement, pulse, blood oxygen level, blood pressure, etc. and send the data to the SleepX app on the user smartphone. Unique algorithms combine all data in real time and decide when to activate the vibration, at what intensity, and its duration. The gentle vibration takes you out of deep sleep into a lighter phase, a transition that trains user to breathe properly. Over a short amount of time, user’s brain and body use biofeedback to teach itself to sleep in the correct position and proper breathing technique on its own, leading to improved night breathing over time. At the user's choice, it is possible to receive comprehensive statistical reports on sleep quality and sleep health, as well as alerts about critical health changes that require consultation and follow-up. In the coming months, the company plans to launch the SleepX APP on the APPLE STORE for iPhone users and start marketing DreamIT. SleepX is an Israeli research and development company recently acquired by AppYea. The Company has developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the Company plans to start serial production in 2022. The Company currently focuses its activities on the development and commercialization of its flagship product DreamIT. Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details AppYea inc. Bary Molchadsky +1 800-674-3561 info@appyea.com Company Website http://www.appyea.com

July 07, 2022 02:41 AM Eastern Daylight Time

Image
Article thumbnail News Release

US Digestive Health Launches the Largest Installation of Artificial Intelligence (AI) Systems for Colorectal Cancer Screening in the United States

US Digestive Health

US Digestive Health (“USDH”), a network of top-rated gastrointestinal (GI) practices, today announced that it is now offering patients AI-assisted colonoscopy screenings with the country’s largest installation of GI Genius™ intelligent endoscopy modules. In the U.S., colorectal cancer is the third most common form of diagnosed cancer and the second deadliest, with almost 150,000 new cases every year [1]. However, it’s also one of the most treatable cancers, with a 90% survival rate when it is detected and treated early. Colonoscopy has long been considered the gold standard for detecting polyps that can eventually lead to colorectal cancer. Now, patients at USDH have the strength of an AI-assisted option for screening with GI Genius TM — the first and only FDA-cleared, commercially available device that employs AI to help physicians detect polyps. US Digestive Health’s installation of GI Genius TM is the largest in the world and the first in Pennsylvania. The launch will give patients throughout southeastern, southwestern and central Pennsylvania wide-ranging access to the innovative technology and its enhanced capability. “GI Genius TM is a major breakthrough in colorectal cancer screening. In real time, it can help physicians identify hard-to-detect and potentially cancerous polyps,” said Dr. Dale Whitebloom, US Digestive Health’s Chief Medical Officer. “We begin our screening colonoscopies at age 45, which is the most up-to-date recommendation by the U.S. Preventive Services Task Force and American Cancer Society. Adding GI Genius TM gives us yet another tool to help protect our patients from the scourge of cancer.” The GI Genius TM module uses advanced AI software to highlight suspicious areas with a visual marker in real time — serving as the gastroenterologist’s vigilant second observer with a sensitivity rate per lesion of 100% [2]. A study published on March 15 in Gastroenterology, the official medical journal of the American Gastroenterological Society, found that the use of GI Genius TM in conjunction with a colonoscopy can decrease polyp miss rates by nearly 50%, while other studies have shown that AI-assisted colonoscopy can increase detection rates by up to 14% [3],[4]. Jerry Tillinger, CEO of US Digestive Health, said, “Our mission is to prevent colorectal cancer, and AI-assisted colonoscopy is an incredible advancement in protecting the people of Pennsylvania from this terrible disease. We’re proud to collaborate with Medtronic, as well as our endoscopy partners, AMSURG and PE GI Solutions, to roll out the largest installation of GI Genius TM not only in the United States but also in the world. As a result, US Digestive Health patients now have access to GI Genius TM -assisted colonoscopies.” US Digestive Health was formed in 2019 by Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, in partnership with member practice partner physicians. For more information or to schedule a GI Genius TM -enabled colonoscopy, please visit https://usdigestivehealth.com/. ______________________________________________________________________________________ [1] Cancer.Net. Colorectal Cancer: Statistics. January 2020. Available at: https://www.cancer.net/cancer-types/colorectal-cancer/statistics. Accessed January 22, 2021. [2] Sensitivity calculated as true positive frame rate. GI Genius™ intelligent endoscopy module [instructions for use]. Mansfield, MA: Medtronic; 2021. [3] Hassan C, et al. New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection. Gut. 2020;69(5):799-800 [4] Repici A, Badalamenti M, Maselli R, et al. Efficacy of real-time computer-aided detection of colorectal neoplasia in a randomized trial. Gastroenterology. 2020; 159:512–520.e7. About US Digestive Health US Digestive Health oversees a network of over 150 gastroenterology providers and has 26 locations, 15affiliated ambulatory surgery centers, and more than 800 total employees in Pennsylvania. They are at the forefront of the rapidly advancing science of digestive health, bringing new insight into the care, treatment, and prevention of digestive health disorders. The practices that have joined the US Digestive Health network are: Digestive Disease Associates of Berks and Chester Counties; Main Line Gastroenterology Associates of Chester, Delaware, and Montgomery Counties; Regional Gastroenterology of Lancaster County; Carlisle Digestive Disease Associates of Cumberland County; West Chester Gastrointestinal Group of Chester County; Hillmont G.I. of Montgomery County; The Center for GI Health of Bucks and Montgomery Counties; and Gastrointestinal Specialists of Philadelphia, Montgomery, and Bucks Counties. About Amulet Capital Partners, LP Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit www.amuletcapital.com. INDICATIONS GI Genius™ intelligent endoscopy module is a computer-assisted reading tool designed to aid endoscopists in detecting colonic mucosal lesions (such as polyps and adenomas) in real time during standard white light endoscopy examinations of patients undergoing screening and surveillance endoscopic mucosal evaluations. The GI Genius™ computer-assisted detection device is limited for use with standard white-light endoscopy imaging only. This device is not intended to replace clinical decision-making. ### Contact Details LevLane Lauren Stralo +1 484-747-9692 lstralo@levlane.com Company Website https://usdigestivehealth.com

July 06, 2022 08:03 AM Eastern Daylight Time

Article thumbnail News Release

Kidney Transplants Continue to Rise Nationally

United Network for Organ Sharing

A new report shows continued increases in the number of lifesaving kidney transplants taking place across the country, according to data compiled by United Network for Organ Sharing (UNOS). UNOS is the engine that powers the national donation and transplant system, serving as the Organ Procurement and Transplantation Network (OPTN) under federal contract. Following changes in March of 2021 to how deceased donor kidneys were allocated, an early data report showed increases in the number of transplants and expanded equity, especially amongst historically marginalized groups. Now, with one full year of post-implementation data available, the new report shows a 16% increase in kidney transplants across the nation, including for the following groups: 23% for Black patients 29% for Hispanic patients 20% for Asian patients 36% for people with longer times on dialysis 63% for pediatric patients 79% for highly-sensitized patients, or those with more difficulty finding a compatible donor organ This data remains consistent with previous reports that showed similar, positive results for the same patient groups. “We continue to see positive results for patients and families following changes we enacted in 2021,” said UNOS CEO Brian Shepard. “Getting to this point means bringing together a diverse group of physicians, patients, advocates, donor families and others to develop policies that continue to improve the national system and save more lives. But even as we see transplants rise and equity improving, there is more work to do and we are committed to building on these and other successes.” The report also showed an increase in the number of kidneys that were not utilized. In keeping with the National Academies of Sciences, Engineering and Math (NASEM) recommendations, UNOS and stakeholders across the nation are committed to working together to find new ways to incentivize the use of more kidneys. Ongoing efforts to achieve this goal include the UNOS-developed offer-filters tool for transplant programs, expanding the use of predictive analytics in decision making, and more. Additionally, the OPTN Kidney Transplantation Committee will continue to monitor the impact and results of this policy. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 newsroom@unos.org Company Website https://unos.org

July 05, 2022 01:25 PM Eastern Daylight Time

Article thumbnail News Release

Vascudyne Receives BioBusiness Award from Regenerative Medicine Minnesota for Treatment of Nerve Injury

Vascudyne, Inc.

Vascudyne, Inc., a biotechnology trailblazer in regenerative medicine, announced today that it was awarded a grant from Regenerative Medicine Minnesota for a project titled “Development of a Peripheral Nerve Wrap Using Regenerative Engineering Tissue Tube”. The one-year, $100,000 grant will commence in June 2022 and utilize Vascudyne’s TRUE™ Tissue technology that is unique and 100% natural. The TRUE Tissue allogeneic biomaterial is completely biological, non-immunogenic and regenerates by the host. Nothing synthetic or artificial is ever used in the manufacturing process, in contrast to other regenerative medicine soft tissue biomaterials made from synthetic polymer-based scaffolds that slowly degrade in the body and may lead to adverse immune response. Chronic nerve compression is one of the most common peripheral nerve injuries with carpal tunnel syndrome being the most common type of nerve compression affecting 3-6% of the general population. Tissues isolated from the patient are used in surgery but have shortcomings such as donor site morbidity, limited availability, and risk of surgical complications. “We are excited to expand our TRUE Tissue platform technology to other soft tissue applications such as nerve repair,” said Rick Murphy, Vascudyne’s Chief Operating Officer. “The exquisite regenerative properties of our 100% biological biomaterial combined with its non-immunogenic properties and off-the-shelf availability are a perfect fit for addressing the challenging nerve injury applications. Demonstrating these benefits in a preclinical nerve injury model will greatly advance the field of peripheral nerve injury and offer a promising alternative to current treatments that often lack complete and functional nerve repair.” Vascudyne has prioritized commercialization of its cardiovascular products and recently announced the first clinical results of its regenerative vascular conduit for hemodialysis access. “While we are initially focusing on cardiovascular applications for our TRUE Tissue technology, we continue research and development efforts in other soft tissue applications such as nerve injury repair,” stated Dr. Zeeshan Syedain, Vascudyne’s Chief Scientific Officer. “This grant from the Regenerative Medicine Minnesota will help accelerate our preclinical animal study timeline and demonstrate safety and efficacy of the TRUE Tissue technology as a peripheral nerve wrap.” Vascudyne licensed its proprietary TRUE Tissue technology developed by world renowned tissue engineering leader Robert Tranquillo, PhD, Distinguished McKnight University Professor, and his colleagues from the University of Minnesota in 2017. TRUE Tissue products are not available for commercial sale. About Vascudyne Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a mission to improve patient care with regenerative biomaterials that are inspired by nature. Vascudyne, a privately held company founded in 2014, uses the TRUE™ Tissue technology to develop TRUE to Nature™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/. About TRUE™ Tissue Technology TRUE™ Tissue is developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. The TRUE™ Tissue technology can be readily shaped into tubes, sheets, and other geometries making it suitable for many soft tissue applications, is mechanically comparable to native tissues, and is a ready to use, off-the-shelf allograft. Forward Looking Statements This announcement contains forward-looking statements. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements relate to future events or Vascudyne’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Vascudyne’s actual results, performance or achievements to be materially different. Vascudyne undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. Contact Details Vascudyne, Inc. Sandy Williams, Marketing Director +1 952-412-5975 swilliams@vascudyne.com Company Website https://vascudyne.com/

June 30, 2022 09:23 AM Eastern Daylight Time

Image
1 ... 159160161162163 ... 227